Original

Comparison of the Characteristics of Rheumatoid Arthritis Patients in Clinical Trials and Clinical Practice

Waki MORITA, et al. 111

Forum

Contribution of Visiting CRC to Clinical Trials in Ehime University Hospital Clinical Research Trial Network

Chieko YAMASAKI, et al. 117

Development of Training Materials for Clinical Research Education Utilizing Simulated Registration to UMIN-CTR Operated by the University hospital Medical Information Network (UMIN)

Naoki MATSUMOTO, et al. 121

Proceedings of the 31th Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics

Contents 129
Symposium 3 “Cell Therapy” 133
Symposium 9 “Clinical Pharmacology of Drug Transporters” 143
Symposium 14 “Strategies for the Promotion of Clinical Trials in Japan” 155
Symposium 15 “Molecular-Targetted Drugs and Biomarkers” 165
Symposium 18 “The Contribution of Clinical Pharmacology Departments to Study the Pathological Pharmacokinetics” 171
Symposium 19 “Chronic Kidney Disease (CKD) and New Therapeutic Approach” 183
Symposium 23 “Perspective of Order-Made Pharmacotherapy in Psychiatry” 195

Drug Information 91E

Information for Authors 95E

Announcements 97E
Proceedings of the 31th Annual Meeting of the Japanese Society of Clinical Pharmacology
and Therapeutics

December 1–3, 2010 (Kyoto)
President: Ken-ichi INUI (Emeritus Professor, Kyoto University/President, Kyoto Pharmaceutical University)

Symposium 3 “Cell Therapy”
Summary
S3–1 A New Era of Adaptive T Cell Therapy for Cancer
Takafumi KIMURA, et al. 133
Hiroaki IKEDA 135
S3–2 Clinical Trial for Osteonecrosis Using Autologous Mesenchymal Stem Cells
Tomoki AOYAMA, et al. 137
S3–3 Treatment of Retinal Diseases Using iPS Cells
Masayo TAKASHI 139
S3–4 The Trend of iPS Cell Research
Takashi AOI 141

Symposium 9 “Clinical Pharmacology of Drug Transporters”
S9–1 Clinical Significance of Renal Drug Transporters in Human
Hideyuki MOTOHASHI 143
S9–2 SLC02B1 Gene Polymorphisms in Humans
Yukie ANDO, et al. 145
S9–3 Renal Tubular Excretion of Uremic Toxins: A Novel Therapeutic Modality for Chronic Kidney Disease by Enhancement of Uremic Toxin Transporter
Takehiro SUZUKI, et al. 147
S9–4 Drug Transport Mediated by a Novel Human Voltage-Driven Organic Anion Transporter NPT4 (SLC17A3)
Naohiko ANZAI 149
S9–5 Different Influences of CYP2C19 Gene Polymorphisms on the Antiplatelet Effect of Clopidogrel and Ticlopidine
Akimitsu MAEDA, et al. 151
S9–6 Toward PGx-Guided “Personalized Medicine”:
Multicenter Randomized Pharmacogenomic Trial for Tuberculosis Therapy
Masako OHNO, et al. 153

Symposium 14 “Strategies for the Promotion of Clinical Trials in Japan”
Summary
Hideo KUSUOKA, et al. 155
S14–1 The Present Situation and Prospect of Clinical Trials in the National Hospital Organization
Suminobu ITO 157
S14–2 About the Enforcement Support of Investigator-Initiated Clinical Trials
Manabu YAMAMOTO 159
S14–3 New Challenge of Proceeding Clinical Study in Chiba University Hospital
Hideki HANAOKA, et al. 161
S14–4 Japan’s Policies for Clinical Studies
Takeyuki SATO 163

Symposium 15 “Molecular-Targetted Drugs and Biomarkers”
S15–1 Genome Biomarker of Molecular Targetting Therapy for Gastrointestinal Disorders
Takahisa FURUTA, et al. 165
S15–2 Biomarker Hunting for Pharmacogenomics
Gozoh TSUJIMOTO 167
S15–3 Omics Drug Discovery and Target Validation
Toshio TANAKA, et al. 169

Symposium 18 “The Contribution of Clinical Pharmacology Departments
to Study the Pathological Pharmacokinetics”
Summary
Masahiro NOMOTO, et al. 171
S18–1 Clinical Pharmacokinetic Studies with Patients on New Drug Applications:
Regulator Views in Japan
Reiko SATO 173
S18–2 Opportunities and Challenges of a University-Based Phase I Research Unit—Experience at the University of Miami—
Richard A. Preston 175
S18–3 Pharmacokinetic Studies in Patients and Applications to the Treatment
Masahiro NOMOTO 179
S18–4 The Remark from the Planners of Pharmacokinetic Study for Special Population
Koji IWASAKI 181
### Symposium 19 “Chronic Kidney Disease (CKD) and New Therapeutic Approach”

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>S19-1</td>
<td>The Basic Concept and Therapeutic Strategy for Chronic Kidney Disease (CKD)</td>
<td>Toshio DOI, et al.</td>
<td>183</td>
</tr>
<tr>
<td>S19-2</td>
<td>Role of Endothelial Dysfunction in Cardiorenal Syndrome</td>
<td>Seiji UEDA, et al.</td>
<td>187</td>
</tr>
<tr>
<td>S19-3</td>
<td>Strategies for Therapeutic Targeting of the BMP4-Smad1 Signaling Pathway in Diabetic Nephropathy</td>
<td>Hideharu ABE</td>
<td>189</td>
</tr>
<tr>
<td>S19-4</td>
<td>Chronic Kidney Disease and Mineralocorticoids</td>
<td>Miki NAGASE</td>
<td>191</td>
</tr>
<tr>
<td>S19-5</td>
<td>New Strategy for Overcoming CKD with the RAS Inhibitors</td>
<td>Akira NISHIYAMA</td>
<td>193</td>
</tr>
</tbody>
</table>

### Symposium 23 “Perspective of Order-Made Pharmacotherapy in Psychiatry”

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>S23-1</td>
<td>Predictors of Side Effects Induced by Atypical Antipsychotics</td>
<td>Yutaro SUZUKI, et al.</td>
<td>195</td>
</tr>
<tr>
<td>S23-2</td>
<td>Possibility of Pharmacogenetic Approach for Prediction and Personalized Medication in Major Depressive Disorder Treatment</td>
<td>Masaki KATO</td>
<td>199</td>
</tr>
<tr>
<td>S23-3</td>
<td>Clinical Pharmacogenetics in the Treatment of Schizophrenia</td>
<td>Norio YASUI-FURUKORI</td>
<td>201</td>
</tr>
<tr>
<td>S23-4</td>
<td>Perspective of Order-Made Pharmacotherapy in Anxiety Disorder</td>
<td>Takashi WATANABE, et al.</td>
<td>203</td>
</tr>
</tbody>
</table>